International consensus statement on major depressive disorder
- PMID: 20371035
- DOI: 10.4088/JCP.9058se1c.08gry
International consensus statement on major depressive disorder
Abstract
Because considerable variability exists between countries in the management of major depressive disorder, experts in psychiatry gathered for the International Consensus Group on Depression to outline a universal treatment algorithm for this illness. The experts decided to adapt the existing treatment algorithm developed in Japan and discuss strategies for clinical issues that have been problematic in some countries. Specific recommendations were made by the consensus group for screening for, diagnosing, and treating depression, which include periodically screening all patients for depression, completing a differential diagnosis of depression, referring to a psychiatric specialist if needed, establishing a therapeutic alliance with patients and their families, choosing and optimizing the dose of appropriate antidepressants based on individual patient's needs, and incorporating nonpharmacologic treatment strategies as necessary.
Similar articles
-
Major depressive disorder treatment guidelines in America and Europe.J Clin Psychiatry. 2010;71 Suppl E1:e04. doi: 10.4088/JCP.9058se1c.04gry. J Clin Psychiatry. 2010. PMID: 20371031
-
Major depressive disorder treatment guidelines in China.J Clin Psychiatry. 2010;71 Suppl E1:e06. doi: 10.4088/JCP.9058se1c.06gry. J Clin Psychiatry. 2010. PMID: 20371033
-
Major depressive disorder treatment guidelines in Japan.J Clin Psychiatry. 2010;71 Suppl E1:e05. doi: 10.4088/JCP.9058se1c.05gry. J Clin Psychiatry. 2010. PMID: 20371032
-
Major depressive disorder, mental health care, and the use of guidelines in the Middle East.J Clin Psychiatry. 2010;71 Suppl E1:e07. doi: 10.4088/JCP.9058se1c.07gry. J Clin Psychiatry. 2010. PMID: 20371034
-
Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression.CNS Spectr. 2007 Aug;12(8 Suppl 13):1-27. CNS Spectr. 2007. PMID: 17986951 Review.
Cited by
-
Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.CNS Spectr. 2014 Dec;19(6):528-34. doi: 10.1017/S109285291300103X. Epub 2014 Mar 18. CNS Spectr. 2014. PMID: 24642260 Free PMC article.
-
A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in Japan.Int Clin Psychopharmacol. 2016 Jan;31(1):8-19. doi: 10.1097/YIC.0000000000000105. Int Clin Psychopharmacol. 2016. PMID: 26513202 Free PMC article. Clinical Trial.
-
Rediscovering trazodone for the treatment of major depressive disorder.CNS Drugs. 2012 Dec;26(12):1033-49. doi: 10.1007/s40263-012-0010-5. CNS Drugs. 2012. PMID: 23192413 Free PMC article. Review.
-
Factors impacting the efficacy of venlafaxine extended release 75-225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan.Neuropsychiatr Dis Treat. 2018 May 16;14:1261-1272. doi: 10.2147/NDT.S146428. eCollection 2018. Neuropsychiatr Dis Treat. 2018. PMID: 29844674 Free PMC article.
-
Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.Mol Psychiatry. 2024 Aug;29(8):2575-2586. doi: 10.1038/s41380-024-02445-4. Epub 2024 Mar 19. Mol Psychiatry. 2024. PMID: 38503923 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical